Corbus Pharmaceuticals (CRBP)
Develops CRB-701 for oncology and CRB-913 for obesity.
Something off on this page? Send us feedback.
Develops clinical-stage candidates in oncology and obesity. The pipeline pairs CRB-701, a licensed Nectin-4-targeting antibody-drug conjugate, with CRB-913, an orally delivered peripherally restricted CB1 inverse agonist, and uses external service providers across development.
Develops clinical-stage therapies in oncology and obesity. CRB-701 is a Nectin-4-targeting antibody-drug conjugate for Nectin-4-expressing tumors, licensed from CSPC Megalith. FDA has granted the candidate Fast Track designations for head and neck squamous cell carcinoma and cervical cancer. CRB-913 is an orally delivered, peripherally restricted CB1 inverse agonist for obesity.
Clinical development relies on a small internal workforce with consultants, CROs, and other third parties supporting preclinical, clinical, manufacturing, and regulatory work. Neither lead program is commercial; the licensed pipeline follows unsuccessful Phase 3 studies of the earlier lenabasum program.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 26, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $40 | Target: $35 |
| Aug 13, 2026 | Mizuho Securities | Target | Target: $44 | Target: $33 |
| May 22, 2026 | Mizuho Securities | Target | Target: $39 | Target: $44 |
| May 12, 2026 | Jefferies | Target | Target: $46 | Target: $33 |
| Oct 29, 2025 | Mizuho Securities | Target | Target: $74 | Target: $39 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $117.9M · Total debt $4.3M · Total assets $127.0M · Shareholders' equity $102.2M
- Revenue
- $0
- Operating income
- −$36.2M
- Net income
- −$35.0M
No dividends on record.
| Insiders | 3.01% | 581.6K shares | |
|---|---|---|---|
| 13 holders · as of Sep 15, 2026 | |||
| Strategic holders | 24.61% | 4.76M shares | |
| 3 holders · as of Jul 27, 2026 | |||
| Other | 72.38% | 14.00M shares | |
| remainder | |||
19.34M company shares as of Sep 23, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Cormorant Asset Management, LPStrategic10 percent owner | 12.12% | 2.34M | filed Dec 15, 2025 |
Aberdeen Group plcStrategic | 6.83% | 1.32M | filed Jan 16, 2026 |
BlackRock, Inc.Strategic | 5.65% | 1.09M | filed Jul 27, 2026 |
Yuval CohenInsiderdirector, officer: Chief Executive Officer | 0.81% | 157,316 | filed Aug 10, 2026 |
Dominic SmethurstInsiderofficer: Chief Medical Officer | 0.46% | 89,790 | filed Mar 4, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Yong Ben | director | −2,000 | $7.84 |
| Aug 11, 2026 | Nishant C. Saxena | officer: Chief Business Officer | +2,600 | $9.63 |
| Aug 7, 2026 | Sean F. Moran | officer: Chief Financial Officer | −12,000 | $10.08 |
| Aug 7, 2026 | Yuval Cohen | director, officer: Chief Executive Officer | −17,000 | $10.08 |
| Jun 10, 2026 | John Kenneth Jenkins | director | −4,800 | $7.91 |
- Pfizer
Commercial Nectin-4 ADC rival in urothelial cancer
- Eli Lilly
Marketed and pipeline obesity-drug rival across incretin therapies
- Novo Nordisk (ADR)
Global obesity-drug rival with injectable and oral Wegovy
- Viking Therapeutics
Phase 3 obesity-drug rival with injectable and oral VK2735
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals | $7.78 | −1.27% | $145.9M | — | — | — | — |
| Pfizer | $27.92 | −0.05% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Eli Lilly | $1,152.19 | −1.53% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $38.23 | −2.98% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Viking Therapeutics | $41.09 | +0.59% | $4.77B | — | — | — | — |
| Median | 36.9 | 15.8 | 3.5 | +2.6% |